These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12552793)

  • 21. Blood clots a late hazard for drug-coated stents. The benefits of drug-coated stents come with a price--long term use of clot-preventing drugs.
    Harv Heart Lett; 2006 Aug; 16(12):1-3. PubMed ID: 16918032
    [No Abstract]   [Full Text] [Related]  

  • 22. Late thrombosis a concern with drug-eluting stents.
    Leon MB
    J Interv Cardiol; 2007 Feb; 20(1):26-9. PubMed ID: 17300394
    [No Abstract]   [Full Text] [Related]  

  • 23. The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer.
    Lee YK; Hyung Park J; Tae Moon H; Yun Lee D; Han Yun J; Byun Y
    Biomaterials; 2007 Mar; 28(8):1523-30. PubMed ID: 17157376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems.
    Kavanagh CA; Rochev YA; Gallagher WM; Dawson KA; Keenan AK
    Pharmacol Ther; 2004 Apr; 102(1):1-15. PubMed ID: 15056495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A novel high quality specific antithrombotic drug--hirudin].
    Li T; Wan C; Li Y; Chen H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 1998 Sep; 15(3):306-10. PubMed ID: 12553260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-eluting stents: preventing restenosis.
    Slavin L; Chhabra A; Tobis JM
    Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Coronary stents and anaesthesia].
    Lehot JJ; Staat P; Ffrench P; Vichova Z; Cannesson M
    Ann Fr Anesth Reanim; 2007 Sep; 26(9):784-90. PubMed ID: 17692497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High throughput methods to characterize protein permeation and release.
    Capelle MA; Gurny R; Arvinte T
    Int J Pharm; 2008 Feb; 350(1-2):272-8. PubMed ID: 17997238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma halflife.
    Huhle G; Liebe V; Hudek R; Heene DL
    Thromb Haemost; 2001 May; 85(5):936-8. PubMed ID: 11372692
    [No Abstract]   [Full Text] [Related]  

  • 30. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.
    Sucker C; Zotz RB; Görlinger K; Hartmann M
    Acta Anaesthesiol Scand; 2008 Mar; 52(3):358-62. PubMed ID: 18205897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives.
    Jaffe R; Strauss BH
    J Am Coll Cardiol; 2007 Jul; 50(2):119-27. PubMed ID: 17616295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined administration of barbourin--albumin and hirudin--albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta.
    Sheffield WP; Gataiance S; Eltringham-Smith LJ
    Thromb Res; 2007; 119(2):195-207. PubMed ID: 16478628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-stent thrombosis after discontinuation of antiplatelet therapy 2 years after DES implantation: a case report.
    De Luca G; Carbone G; Maione A; Gregorio G
    Int J Cardiol; 2007 Apr; 116(3):399-400. PubMed ID: 17258334
    [No Abstract]   [Full Text] [Related]  

  • 34. Bare metal stents: no longer passé?
    Bavry AA; Bhatt DL
    J Invasive Cardiol; 2006 Sep; 18(9):403-4. PubMed ID: 16954576
    [No Abstract]   [Full Text] [Related]  

  • 35. Current issues in management of thromboses.
    Clark S
    Lancet; 1995 Jul; 346(8967):113-4. PubMed ID: 7603184
    [No Abstract]   [Full Text] [Related]  

  • 36. TCT Daily: new trials set to examine drug-eluting stents: doctors urged to weigh benefits, risks of drug-eluting stents on per patient basis.
    J Interv Cardiol; 2007 Feb; 20(1):33. PubMed ID: 17300397
    [No Abstract]   [Full Text] [Related]  

  • 37. Recombinant hirudin as anticoagulant during cardiopulmonary bypass.
    Riess FC; Kormann J; Poetzsch B
    Anesthesiology; 2000 Dec; 93(6):1551-2. PubMed ID: 11149460
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug-eluting coronary stents: what are the risks?
    Kersten JR; Fleisher LA
    Anesthesiology; 2007 May; 106(5):898-900. PubMed ID: 17457119
    [No Abstract]   [Full Text] [Related]  

  • 39. Glow discharge plasma deposition (GDPD) technique for the local controlled delivery of hirudin from biomaterials.
    Kim DD; Takeno MM; Ratner BD; Horbett TA
    Pharm Res; 1998 May; 15(5):783-6. PubMed ID: 9619790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries.
    Artang R; Dieter RS
    Am J Cardiol; 2007 Apr; 99(8):1039-43. PubMed ID: 17437724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.